84-1175-59　IGFBP5 (Insulin-like Growth Factor-binding Protein 5, IBP-5, IGF-binding Protein 5, IGFBP-5, IBP5) 100ul　I7661-16T6

特徴

• The insulin like growth factors (IGFs) are the major growth- promoting factors in the plasma.
• IGFs are secreted by a variety of cells and exert a multitude of effects on cellular survival, growth and differentiation.
• The A and B domains of IGFs are identical to insulin.
• IGF initiates their biological action through binding to the type IGF receptor (IGF-1R), a heterotrimeric protein complex with a tyrosine kinase activity.
• The IGF-IIR lacks the kinase activity and is actually identical to the mannose- 6-phophate receptor.
• Unlike most other peptide hormones, IGFs are complexed with specific binding proteins in the plasma known IGF Binding proteins (IGFBPs).
• At least 6 related IGFBPs (IGFBP1-6) have been well characterized.
• Recently, IGFBP-7/Mac25/prostacyclin- stimulating factor (PSF)/tumor adhesion factor (TAF) was originally identified as a cDNA derived from leptomeninges.
• These proteins are present in plasma in high concentration as compared to the membrane IGFRs.
• Therefore, IGFBPs have the potential to modulate the IGF action.
• IGFBPs have been shown to either inhibit or stimulate the IGF effects.
• The primary structures of mammalian IGFBPs appear to contain three distinct domains of roughly equivalent sizes: the conserved N-terminal domain, the highly variable mid region, and the conserved C-terminal domain.
• Human IGFBPs share approximately 36% identity.
• Recently several groups of cysteine-rich proteins with discrete, but striking, structural and functional similarities to the IGFBPs.
• This has led to the proposal of an IGFBP superfamily, comprised of the IGFBPs and these IGFBP-related proteins (IGFBP-rP1-9).
• Human IGFBP-5 is a 252aa mature protein that is expressed by fibroblasts, myoblasts and osteoblasts, making it the predominant IGFBP found in bone extracts.
• IGFBP-5 has a strong affinity for hydroxyapatite, allowing it to bind to bone cells.
• When bound to extracellular matrix, IGFBP-5 is protected from proteolysis and potentiates IGF activity, but when it is soluble, IGFBP-5 is cleaved to a biologically inactive 21kD fragment.
• Applications:Suitable for use in ELISA, Immunoprecipitation and Western Blot.
• Other applications not tested.
• Recommended Dilution:Western Blot: 1:1000-1:2000ELISA: 1:10,000 (50-100ng control antigen/well)
• Immunoprecipitation: 4-5ul per assayOptimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Aliquots are stable for at least 12 months.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.